Literature DB >> 26261529

Association between PD-1/PD-L1 and T regulate cells in early recurrent miscarriage.

Guiyu Li1, Caixia Lu2, Jing Gao2, Xietong Wang3, Huanling Wu4, Chao Lee2, Baoxiang Xing2, Qi Zhang5.   

Abstract

In this study, we try to testify the relationship between the programmed cell death receptor-1 (PD-1)/programmed cell death ligand 1 (PD-L1) passway and Treg cells in maternal-fetal immune regulation through PD-1 blockade on lymphocytes of normal early pregnancy in vitro and investigation of the PD-1 and PD-L1 changes in early recurrent miscarriage patients. CD4+ CD25+ Treg cells and PD-1 (CD279) positive cell were detected in deciduas in early recurrent miscarriage patients by flow cytometry. And the normal early pregnant women were as controls. Meanwhile the mRNA level of PD-1 and molecular expression of PD-L1 in deciduas of early recurrent miscarriage patients were detected by real time RT-PCR test and Immunohistochemical staining respectively. Also through antibody blocking assay to block PD-1 on lymphocytes of normal early pregnancy in vitro further testify the relationship between PD-1/PD-L1 and Treg cells, the results were analyzed by flow cytometry. CD4+ CD25+ Treg cells decreased both in deciduas in RM (P < 0.05), and for all almost 100% Treg cells (CD4+ CD25+) expressed PD-1, but there was no difference between the PD-1 positive cells in decidual lymphocytes in RM and that in normal pregnancy women (P > 0.05). PD-L1 mRNA in deciduas decreased in RM (P < 0.001), but PD-1 mRNA no difference (P > 0.1). After PD-1 blockade there was no change in CD4+ CD25+ Treg cells percentage, while the CD4+ T cell percentage increased (P < 0.01), as well as the level of IFN-gamma in cells supernatant (P < 0.01). PD-1 blockade has a little influence on the number of Treg cells, and may lead to impaired Treg cells function, the decrease of PD-L1 may closely relates to the occurrence of early recurrent miscarriage and implies that Treg cells may through PD-1/PD-L1 pathway play a role of immunosuppression regulation, and the impairment of Treg cells function in recurrent early abortion cases may be due to PD-L1 decrease in deciduas or trophoblast cells rather than PD-1 change.

Entities:  

Keywords:  Early pregnancy; immunoregulation; miscarriage; programmed cell death receptor-1; regulatory T cells

Mesh:

Substances:

Year:  2015        PMID: 26261529      PMCID: PMC4525863     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  19 in total

Review 1.  Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self.

Authors:  Shimon Sakaguchi
Journal:  Nat Immunol       Date:  2005-04       Impact factor: 25.606

2.  Differential distribution of CD4(+)CD25(bright) and CD8(+)CD28(-) T-cells in decidua and maternal blood during human pregnancy.

Authors:  T Tilburgs; D L Roelen; B J van der Mast; J J van Schip; C Kleijburg; G M de Groot-Swings; H H H Kanhai; F H J Claas; S A Scherjon
Journal:  Placenta       Date:  2006-01-25       Impact factor: 3.481

3.  Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo.

Authors:  Sigrid E Sandner; Michael R Clarkson; Alan D Salama; Alberto Sanchez-Fueyo; Christoph Domenig; Antje Habicht; Nader Najafian; Hideo Yagita; Miyuki Azuma; Laurence A Turka; Mohamed H Sayegh
Journal:  J Immunol       Date:  2005-03-15       Impact factor: 5.422

Review 4.  CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.

Authors:  Annegret Kuhn; Stefan Beissert; Peter H Krammer
Journal:  Arch Dermatol Res       Date:  2008-11-05       Impact factor: 3.017

5.  A link between PDL1 and T regulatory cells in fetomaternal tolerance.

Authors:  Antje Habicht; Shirine Dada; Mollie Jurewicz; Brian T Fife; Hideo Yagita; Miyuki Azuma; Mohamed H Sayegh; Indira Guleria
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

Review 6.  TH17 cells and regulatory T cells in primary immunodeficiency diseases.

Authors:  Hans D Ochs; Mohamed Oukka; Troy R Torgerson
Journal:  J Allergy Clin Immunol       Date:  2009-05       Impact factor: 10.793

7.  Proportional change of CD4+CD25+ regulatory T cells in decidua and peripheral blood in unexplained recurrent spontaneous abortion patients.

Authors:  Hui Yang; Lihua Qiu; Guangjie Chen; Zi Ye; Caijun Lü; Qide Lin
Journal:  Fertil Steril       Date:  2007-06-04       Impact factor: 7.329

Review 8.  Chemokines and chemokine receptors: an overview.

Authors:  Raffaella Bonecchi; Emanuela Galliera; Elena Monica Borroni; Massimiliano Marco Corsi; Massimo Locati; Alberto Mantovani
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

9.  A critical role for the programmed death ligand 1 in fetomaternal tolerance.

Authors:  Indira Guleria; Arezou Khosroshahi; Mohammed Javeed Ansari; Antje Habicht; Miyuki Azuma; Hideo Yagita; Randolph J Noelle; Anthony Coyle; Andrew L Mellor; Samia J Khoury; Mohamed H Sayegh
Journal:  J Exp Med       Date:  2005-07-18       Impact factor: 14.307

Review 10.  Regulatory T-cells and immune tolerance in pregnancy: a new target for infertility treatment?

Authors:  Leigh R Guerin; Jelmer R Prins; Sarah A Robertson
Journal:  Hum Reprod Update       Date:  2009-03-11       Impact factor: 15.610

View more
  11 in total

1.  Tumor-Associated CD163+ M2 Macrophage Infiltration is Highly Associated with PD-L1 Expression in Cervical Cancer.

Authors:  Fan Guo; Yang-Chun Feng; Gang Zhao; Ran Zhang; Zhen-Zhen Cheng; Wei-Na Kong; Hui-Li Wu; Bin Xu; Xiang Lv; Xiu-Min Ma
Journal:  Cancer Manag Res       Date:  2020-07-15       Impact factor: 3.989

2.  Extracellular vesicles generated by placental tissues ex vivo: A transport system for immune mediators and growth factors.

Authors:  Wendy Fitzgerald; Nardhy Gomez-Lopez; Offer Erez; Roberto Romero; Leonid Margolis
Journal:  Am J Reprod Immunol       Date:  2018-05-04       Impact factor: 3.886

3.  Elevated Expression of Programmed Death-1 and Programmed Death Ligand-1 Negatively Regulates Immune Response against Cervical Cancer Cells.

Authors:  Zhifang Chen; Nannan Pang; Rong Du; Yuejie Zhu; Lingling Fan; Donghui Cai; Yan Ding; Jianbing Ding
Journal:  Mediators Inflamm       Date:  2016-09-05       Impact factor: 4.711

4.  The relationship between the PD-1/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance.

Authors:  Yang-Chun Feng; Wen-Li Ji; Na Yue; Yan-Chun Huang; Xiu-Min Ma
Journal:  Cancer Manag Res       Date:  2018-01-18       Impact factor: 3.989

5.  Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy.

Authors:  Elizabeth Ann L Enninga; Susan M Harrington; Douglas J Creedon; Rodrigo Ruano; Svetomir N Markovic; Haidong Dong; Roxana S Dronca
Journal:  Am J Reprod Immunol       Date:  2017-12-04       Impact factor: 3.886

Review 6.  Regulation of the innate immune cells during pregnancy: An immune checkpoint perspective.

Authors:  Wen-Xuan Li; Xiang-Hong Xu; Li-Ping Jin
Journal:  J Cell Mol Med       Date:  2021-10-28       Impact factor: 5.310

7.  Association of genetic variants of PD1 with recurrent pregnancy loss.

Authors:  Yuko Hayashi; Takeshi Nishiyama; Masahiro Nakatochi; Shugo Suzuki; Satoru Takahashi; Mayumi Sugiura-Ogasawara
Journal:  Reprod Med Biol       Date:  2018-03-23

8.  Estradiol Attenuates the Severity of Primary Toxoplasma gondii Infection-Induced Adverse Pregnancy Outcomes Through the Regulation of Tregs in a Dose-Dependent Manner.

Authors:  Jingfan Qiu; Rong Zhang; Yanci Xie; Lijuan Wang; Ke Ge; Hao Chen; Xinjian Liu; Jiangping Wu; Yong Wang
Journal:  Front Immunol       Date:  2018-05-18       Impact factor: 7.561

Review 9.  Immune Checkpoint Molecules in Reproductive Immunology.

Authors:  Eva Miko; Matyas Meggyes; Katalin Doba; Aliz Barakonyi; Laszlo Szereday
Journal:  Front Immunol       Date:  2019-04-18       Impact factor: 7.561

Review 10.  The Role of B7 Family Molecules in Maternal-Fetal Immunity.

Authors:  Yongbo Zhao; Qingliang Zheng; Liping Jin
Journal:  Front Immunol       Date:  2020-03-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.